From: Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
Patient | Sex | Age at diagnosis | Clinical subtype | p53 activity | First line treatment | Interval between induction therapy and As2O3 consolidation (months) | Disease status at time/after of A2So3 | Treatment duration (weeks) | OS since diagnosis (months) | Death | OS since arsenic (months) | Duration of response since As2O3 (months) | Progression |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ATL 6 | M | 51.6 | Chronic | F | AZT-IFN-VP16 | 24.4 | SD/SD | 4 | 53 | Yes | 28 | 22 | Yes |
ATL 9 | M | 50.6 | Chronic | F | CHOP like | 20.1 | CR/CR | 6 | 48 | Yes | 28 | 25 | Yes |
ATL 11 | M | 27.7 | Chronic | F | LSG 15 + AZT-IFN | 13.2 | VGPR/CR | 6 | 97 | Yes | 83 | 73 | Yesa |
ATL 7 | F | 59.8 | Acute | F | CHOP like | 6.2 | PD/PD | 4 | 8 | Yes | 1 | NA | Yes |
ATL 14 | F | 35.1 | Acute | NF | Alemtuzumab-CHOP | 2.2 | CR/CR | 4 | 12 | Yes | 10 | 5 | Yes |
ATL 43 | F | 66.3 | Lymphoma | F | CHOP like | 6.3 | CR/CR | 8 | 19 | Yes | 12 | 5 | Yes |
ATL 44 | F | 54.8 | Lymphoma | F | CHOP like | 3.8 | VGPR/CR | 8 | 36 | Yes | 32 | 29 | Yes |
ATL 64 | M | 63.1 | Lymphoma | ND | CHOP/DHAOx | 13 | CR/CR | 8 | 65 | No | 51 | 51 | No |
ATL 65 | M | 54.4 | Lymphoma | ND | CHOP | 4 | PR/PR | 16 | 41 | Yes | 36 | 10 | Yes |